Rona’s Sanofi-Sourced siRNA Demonstrates Early Efficacy in Dyslipidaemia Treatment

Rona's siRNA Therapy:
Rona's siRNA therapy, sourced from Sanofi, has shown early promise in treating dyslipidaemia, a condition characterized by abnormal levels of lipids in the blood1.

Liver-Directed Therapies:
The company's pipeline includes a range of liver-directed siRNA therapies being developed for obesity, metabolic disorders, and other conditions1.

Background on siRNA:
siRNA (small interfering RNA) is a type of RNA interference (RNAi) therapy that has the potential to treat a wide range of diseases by silencing specific genes. This technology is based on Nobel Prize-winning science and has been clinically validated2.

Strategic Partnerships:
Sanofi and Alnylam Pharmaceuticals have a strategic alliance focused on developing RNAi therapeutics for rare genetic diseases. This partnership has been restructured to streamline and optimize the development and commercialization of these products2.

Future Developments:
The success of Rona's siRNA therapy in dyslipidaemia could pave the way for further developments in treating lipid disorders and other metabolic conditions using RNAi technology.

Sources:

1. https://firstwordpharma.com/story/5913264

2. https://www.sanofi.com/en/media-room/press-releases/2018/2018-01-07-20-00-00-1284695